Keros Therapeutics Q3 Results Scheduled for November 11
Keros Therapeutics is set to report Q3'26 results on November 11. EPS is estimated at $(0.94); the release time is not specified.
Related stories
Array Technologies to Merge With Shoals in an All-Stock Deal
Array Technologies and Shoals will combine in an all-stock transaction.
M impact | EQUITY | Nov 04, 2026, 02:21 PM UTC
Enviri Exits Deutsche Bahn Contract, Expects $19 Million Gain
Enviri released Harsco Rail from its Deutsche Bahn contract after repaying approximately $73 million in advances. The company expects a net gain of approximately $19 million with t
M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC
Vivakor Highlights Potential Annual Service Revenue Above $2 Million
Direct Midstream’s conditional agreement to operate 52 New Mexico wells could generate more than $2 million in annual service revenue at targeted operating levels, subject to final
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
TeraWulf Gets Google Credit Backing for Anthropic Data Center Project
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
TeraWulf Gets Google Credit Backstop for Anthropic Data-Center Project
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
Freeport Approves $4.5 Billion Bagdad Copper Expansion
Freeport-McMoRan's board approved a $4.5 billion expansion and modernization project at its Bagdad copper and molybdenum operation in Arizona. The project is expected to more than
M impact | EQUITY | Nov 04, 2026, 02:05 PM UTC